Article
EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.
JCI insight - 23 Jan 2026
Ogino Atsuko, Vajdi Amir, Mu Xinmeng Jasmine, Mahadevan Navin R, Ngo Kenneth, Booker Matthew A, Cejas Paloma, Okoro Jeffrey J, Xu Man, Springer Benjamin F, Eschle Benjamin K, Messier Cameron M, Wang Stephen, Syamala Sudeepa, Tamen Rubii M, Adeni Anika E, Chambers Emily S, Canadas Israel, Thai Tran, Christensen Camilla L, Xu Chunxiao, Lizotte Patrick H, Oxnard Geoffrey R, Watanabe Hideo, Long Henry W, Gokhale Prafulla C, Paweletz Cloud P, Sholl Lynette M, Oser Matthew G, Barbie David A, Tolstorukov Michael Y, Jänne Pasi A
Abstract excerpt
Small cell lung cancer (SCLC) transformation is an incompletely characterized mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant cancers, limiting development of optimal treatment approaches. Through single-cell RNA sequencing of malignant pleural effusions from patients who underwent SCLC transformation, we identified heterogeneity and diversity,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.